Longevity InTime: Autonomous AI Institute. Anti-Aging Digital Health Immortality Transhumanist AI Channel
1.03K subscribers
137 photos
55 videos
2 files
2.6K links
NVIDIA inception Member, Nebius AI Discovery Awards semifinalist

Potentially first $1T Longevity BioTech AI company

Part of Longevity Ecosystem
LongevityInTime.com

@PickleballPartners

Shop
https://web.tribute.tg/l/lr

Homes
www.Africa.Villas
Download Telegram
Compound Boosts DNA Repair in Progeria and Down Syndrome Cells, Extends Mouse Lifespan by 8.6%

On November 1, Nature Communications published a study from Elsa Logarinho's group at the University of Porto. The compound UMK57 enhances the protein KIF2C, which disassembles microtubules — filaments of the cell's internal skeleton. In skin cells from patients, it reduced the number of unrepaired DNA breaks, and in progeria mice it increased median lifespan to 17.1 weeks versus 15.7 weeks in untreated controls.

When both DNA strands break, the cell must bring the severed ends together. In 2024, a University of Toronto group described this process: microtubules indent the nuclear envelope, forming a tubular fold that captures the break so the ends can find each other. These folds require dynamic microtubules — some threads grow while others disassemble, a process driven by KIF2C. A 2020 study showed that without KIF2C, repair weakens, breaks accumulate, and their movement through the nucleus is impaired.

Logarinho's group previously found in 2020 that KIF2C levels are lower in elderly human skin cells, and that UMK57 reduces chromosome segregation errors and slows cellular aging. The new work tested whether the compound repairs DNA even without cell division, using cells from two diseases marked by excess DNA damage and accelerated aging: Hutchinson–Gilford progeria syndrome (caused by an LMNA mutation that distorts nuclear shape) and Down syndrome (trisomy 21).

In cells from both diseases, KIF2C was reduced and microtubules were abnormally stable. UMK57 restored normal microtubule turnover in progeria cells and lowered unrepaired breaks in both conditions. After treatment with the DNA-breaking drug etoposide, the fraction of cells with nuclear folds increased in healthy cells but not in patient cells; with UMK57, folds appeared in patient cells and breaks decreased. In a separate assay, one hour of etoposide caused breaks in most cells of all types, but after 24 hours patient cells repaired them poorly — UMK57 restored repair to near-healthy levels. Misshapen nuclei and senescent cells also decreased.

Dependence on KIF2C was confirmed by two controls. The analog UMK95 — differing by one chemical group and unable to accelerate microtubule disassembly in vitro — had no effect in progeria cells. When KIF2C was nearly eliminated, UMK57 lost its effect; with partial knockdown, the effect persisted. To exclude division-related DNA damage, healthy cells were arrested in G1 phase, damaged with etoposide, and showed fewer breaks with UMK57.

Progeria mice were treated from week 5 to week 13. Because UMK57 has poor solubility and is rapidly degraded by liver enzymes in vitro, it was delivered continuously via subcutaneous pump. Mice were euthanized upon 25% body-weight loss or severe morbidity. Median survival for 16 treated mice was 17.1 weeks versus 15.7 weeks for 14 controls — an 8.6% increase. Treated mice began losing weight later, and nearly 40% of spinal curvature was corrected. All mice eventually developed cachexia.

The authors note that interventions enhancing DNA repair remain rare because repair requires coordinated action of multiple pathways that "cannot be simply boosted by increasing the activity of only one or a few genes." UMK57 acts at the convergence point where broken ends meet: it potentiates KIF2C and, with it, microtubule renewal. Next steps include experiments in Down syndrome mice, compound optimization, and safety testing. Logarinho is listed as an inventor on a patent covering UMK57 applications.

🔗 Read original →
Hinton Pushes FDA-Style AI Regulation; Critics Call It a Death Sentence for Innovation

Geoffrey Hinton, often called the "godfather of AI," recently told the Guardian that AI models should face FDA-style pre-market approval. He argued companies must prove a model does more good than harm before release, citing the thalidomide tragedy as a warning against the "release first, litigate later" approach.

The analogy is flawed. A molecule like thalidomide can be tested for specific chemical reactions in a lab. A general-purpose neural network generates open-ended code and text; its "harm" depends entirely on the prompt a bad actor injects. What specific "safety proof" could Big Tech possibly submit to a hypothetical AI-FDA?

Critics counter that FDA-style regulation is a proven killer. Protocols demanding "absolute safety" stall vital drugs for years — denying dying patients access to experimental therapies is formalized murder disguised as care. Furthermore, regulatory capture is inevitable: giants like OpenAI and Google would use billions to buy compliance, crush open-source, and cement monopoly.

Hinton's pivot from proving neural nets work to demanding bureaucratic strangulation of the field marks a tragic turn. We cannot let this mindset destroy AI progress the way it crippled implants and prosthetics.

🔗 Read original →
Why Injuries Heal Slower at 45 Than 25: Tendon Core Forms by Age 17

Avi Roy, a biomedical researcher, posted a thread on X on November 2 explaining why recovery slows with age. The core of the Achilles tendon barely renews after age 17, muscle stem cells activate later, and the brain's pain inhibition weakens.

Copenhagen scientists used carbon-14 dating (the "bomb pulse" from 1955–1963 nuclear tests) on 28 Achilles tendon samples. Collagen in the tendon core matched atmospheric levels from the first 17 years of life, indicating virtually no turnover in the load-bearing core after growth stops. Muscle tissue from the same donors showed fresh carbon-14, confirming muscle renews.

Roy reconciles this with studies showing ~1% daily collagen synthesis (implying a 2-month half-life): cells produce collagen, but the structural core isn't replaced. Carbon-14 dating also showed knee cartilage collagen forms in school years. A chemical age marker found intervertebral disc collagen half-life is 95 years (ages 20–40) and 215 years (ages 50–80).

Muscle repair relies on satellite cells. After one resistance session, satellite cells in fast fibers exceeded baseline at 48 hours in 22-year-olds vs 72 hours in 73-year-olds. After 2 weeks immobilization + 4 weeks training, men 61–74 regained strength but fiber size and satellite cell count did not increase; men 21–30 showed growth in both.

Pain inhibition declines with age. In Hamburg, 64 volunteers rated forearm heat pain (0–100) while a foot was in ice water. Pain ratings dropped 9.9 points (ages 20–40), 1.7 (41–60), and 1.6 (61–80); only the youngest drop was statistically significant.

Bone is an exception: 33 patients 65+ with femoral neck fractures fixed with rods healed at 94% vs 89% for younger patients, though mobility was worse.

Tendon adapts to load. In a 1-year trial, 33 people (62–70) did heavy, moderate, or no training. Patellar tendon thickened 6% (heavy), 5% (moderate), 1% (control) (borderline significance). Stretch resistance was maintained only with heavy loading; it fell in the other groups. Biopsies showed core collagen content and cross-links unchanged. Authors suggest the outer tendon region responds to loading.

🔗 Read original →
Low DGLA Levels Let Senescent Cells Survive; Supplementation Triggers Ferroptotic Death

A study from Christopher Wiley's lab at Tufts University, published in Cell on November 2, reveals that the fatty acid DGLA (dihomo-gamma-linolenic acid) selectively kills senescent cells via ferroptosis.

Senescent cells accumulate with age and drive inflammation. The choice between senescence and ferroptosis — an iron-dependent form of cell death driven by lipid peroxidation — was previously unclear. Wiley's 2021 work showed senescent cells convert polyunsaturated fatty acids (PUFAs) into signaling lipids that lock in growth arrest. The new study examined what happens to these fatty acids in membranes.

In human senescent fibroblasts, membrane PUFAs increased overall, but DGLA specifically decreased. DGLA sits between FADS2 (which produces it) and FADS1 (which converts it to arachidonic acid). Across five senescence-inducing methods, the enzyme balance shifted toward FADS1, depleting DGLA.

Supplementing DGLA in culture killed senescent cells within three days via ferroptosis, sparing normal cells. Other omega-6/omega-3 fatty acids lacked this selectivity. An FADS1 inhibitor, which blocks DGLA conversion, also selectively killed senescent cells. Ferroptosis inhibitors (iron chelators, lipophilic antioxidants) rescued the cells; blockers of apoptosis or necroptosis did not. DGLA induced ferroptosis earlier in C. elegans and human cancer cells.

Senescent cells actively take up DGLA via the transporter CD36; blocking CD36 prevented death. They exist in a "sub-ferroptotic stress" state — high free iron, elevated lipoxygenase genes, and baseline membrane peroxidation — held in check by elevated GPX4.

In 22–24-month-old mice, five daily DGLA injections reduced senescence markers (β-galactosidase, p21, p16) in fat and liver after two weeks. Inflammatory genes dropped in fat. Male mice showed improved liver and kidney blood markers in cohorts with worse baseline health. Wiley is an inventor on patents for DGLA-based senolysis.

A human cohort in Kuopio, Finland (131 women, 54 men with obesity) found that an FADS1 variant (CC genotype) impairing DGLA-to-arachidonic conversion correlated with lower p21 expression in subcutaneous fat — significant in women and the combined group.

Separately, Paul Robbins' group at the University of Minnesota found conjugated fatty acids (alternating double bonds), not DGLA, induced ferroptosis in mouse senescent cells.

🔗 Read original →
"Three-Parent IVF" Shows Maternal Mitochondrial Reversion in Children

STAT compiled data from clinics in Greece, the UK, and Ukraine revealing that maternal mitochondria — which the technique aims to replace — have reappeared in several children born via mitochondrial replacement therapy (MRT).

Mitochondria carry their own DNA, inherited maternally; mutations cause severe diseases. MRT transfers the nuclear DNA from a mother's egg or embryo into a donor egg with healthy mitochondria. However, trace maternal mitochondria tag along with the nucleus. In 2016, Shoukhrat Mitalipov's group showed that while donor DNA exceeded 99% in embryos, it gradually lost ground to maternal DNA in derived stem cell lines, a phenomenon dubbed "reversion."

In the Greek infertility trial, one of six children saw maternal mitochondria rise from <1% in the embryo to 30–60% at birth. In Newcastle, UK, where MRT treats mitochondrial disease, three of eight children showed 5%, 12%, and 16% mutant maternal mitochondria in blood. Ukraine's Nadiya clinic provided unpublished data: two of six children exhibited reversion up to 12% and 72%.

Embryologist Jacques Cohen argues reversion is less concerning for infertility — where mothers lack pathogenic mutations — but urges a moratorium for mitochondrial disease until reversion risk is minimized. Bioethicist Guido Pennings proposes testing first in infertile couples without mutations to study reversion safely.

STAT found clinics marketing MRT to older women, claiming young mitochondria aid development. Nadiya embryologist Pavel Mazur transferred nuclei from 19 women aged 36–44 into young donor eggs; only one yielded a chromosomally normal embryo. Conversely, transferring young donor nuclei into patient eggs yielded 40% usable embryos with 70% normal chromosomes — suggesting nuclear DNA damage, not mitochondrial age, drives failure.

In Ghent, Dominik Stoop sought approval for three patient groups. Belgian authorities approved two: mitochondrial disease and oocyte/embryo maturation arrest. The third — advanced maternal age — was rejected. Stoop noted the disease group, seen as least ethically problematic, may be the riskiest.

Mary Herbert (Monash University, formerly Newcastle) cites clinical data showing pathogenic transmission dropped 75–100%, with mutant loads staying below the 50% symptom threshold. Her Australian team is preparing a trial to track mutant load stability over time and across tissues. STAT, November 3

🔗 Read original →
Castrating Adult Male Mice Extends Lifespan More Than Pre-Pubertal Castration (Preprint)

James Nelson's group at the University of Texas Health San Antonio castrated male mice at 20 days (pre-puberty), 60 days (post-puberty), and 240 days (adulthood). Median lifespan reached 841, 887, and 937 days respectively, versus 705 days for sham-operated controls. The preprint appeared on bioRxiv, Oct 24, 2026; a Science news piece followed on Nov 2.

Men live shorter lives than women almost everywhere; in the US in 2024 the gap was 4.9 years. Testes are a prime suspect: a Korean genealogy of 81 eunuchs showed they lived 14–19 years longer than intact men of similar status, though another researcher disputed the records' reliability. In genetically heterogeneous UM-HET3 mice, females consistently outlive males. In a 2023 experiment, Nelson's group castrated such males pre-puberty, raising median lifespan from 771 to 850 days, matching females. The remaining question: from what age do testicular factors — hormones and other secretions — cause harm?

If the pubertal hormone surge sets the damage, surgery at 60 days (after puberty) would be too late; if harm accumulates from youth, surgery at 240 days (before male mortality rises) would be too late. Controls lived shorter than in past studies: median 705 days vs 771. The authors note this may inflate percentage gains: castration at 240 days added 32.9% to 705 days, but only 21.5% to 771. Surgery at 60 days did not differ significantly from 20 days; the authors conclude the pubertal hormone surge does not shorten male life.

From roughly 240 days, mortality in intact males rises, and surgery at this age halted that rise immediately: on the preprint's survival curve, no mouse in this group died for about a year post-operation. Surgery at 240 days worked, so testicular factors act fast, and elevated male mortality depends on their continuous presence. Mice retaining testes until 240 days died less often in late life than those castrated at 20 days, suggesting testes may be beneficial before 240 days. The authors checked for a "reserve" of resilience, but grip strength and frailty indices were no better than in earlier-castrated mice.

A zoo-data analysis in Nature found pre-pubertal castration extended life more than later castration; the preprint authors say their data contradict the "earlier is better" model. The first author of that analysis, Michael Garratt (University of Otago), uninvolved in the mouse study, commented: "I am convinced that late-life castration causes a robust increase in survival." If harmful testicular factors are identified, "castration mimetics" — interventions giving the same lifespan gain without surgery — become possible. Since surgery helps at 240 days, the authors estimate these factors can be blocked in adulthood, preserving any early-life benefit.

Per a review by Nelson's group, 11 of 13 lifespan-extending compounds in the ITP program show stronger effects in males or work only in males. The preprint authors speculate some may suppress testicular harm, and propose testing compounds in males with and without testes to find those acting via testicular factors.

🔗 Read original →
Revel Pharmaceuticals Co-Founder Chooses Enzymatic Protein Repair Over Cellular Reprogramming

Aaron Cravens explained on the November 3 Free Radicals podcast how Revel selects damage targets for repair and why he believes cellular reprogramming — the attempt to revert cells to a youthful state — faces a fundamental delivery barrier.

Collagen and other structural proteins persist for decades while surrounding cells turnover, accumulating chemical damage. Cravens calls this "rust" and selects targets by asking: "What is in old tissue that isn't in young tissue? And if it's in old tissue and not in young tissue — not counting wisdom — we want to get rid of it." His hypothesis: removing all damage distinguishing old from young should restore a youthful state.

Revel largely ignores cellular biology as too complex. Damage has known chemical structures and accumulates linearly with age, whereas senescent cells exist even in the young. Cravens cites the cautionary example of senolytics: senescent cells may be needed for wound healing. Reprogramming, he argues, hits a delivery wall: rejuvenating fibroblasts requires reaching over 90% of them, but delivering DNA-based technologies is difficult.

Revel's first target is carboxymethyllysine (CML), a lysine modified by reactions with sugars and fats. Known for ~40 years, Cravens expected success within six years. CML blocks collagen lysines used for cell binding and triggers systemic inflammation in mice. In humans, CML correlates with mortality: an Italian study of 1,013 people over 65 found the top tertile of plasma CML had a 2.1x higher risk of cardiovascular death over six years (Nature Communications, July 14).

Cravens posits that regeneration weakens because damage has "rusted it in place." Reprogramming proponents hope engineered cells will restore this capacity. Instead, Revel mimics lysosomal storage disease therapy: supplying missing enzymes to clear accumulated waste. For damage accumulating over decades, the body lacks enzymes because evolution didn't require post-reproductive longevity.

On July 14, Revel published in Nature Communications on CMLase, an engineered bacterial enzyme. It converted CML back to lysine: on donor tissue slices, CML staining dropped >70% in a 75-year-old's aorta and >55% in a 74-year-old's skin, reaching levels below a 31-year-old's skin. Cravens aims to apply CMLase first for diabetic retinopathy, kidney disease, and skin aging, hoping for topical use within a year. He plans 4–6 drugs against different damage types and envisions synergy with reprogramming if a working cocktail emerges.

🔗 Read original →
George Murphy Parses First ER-100 Gene Therapy Data: Vision Benefit, Tissue Rejuvenation, and Healthspan Extension Require Different Evidence

On November 2, George Murphy, co-founder of the Boston University Center for Regenerative Medicine, analyzed the initial ER-100 data on The ReProgram podcast. This gene therapy transiently induces retinal cells to produce three proteins to restore a more youthful gene expression pattern.

On October 8, Life Biosciences reported that in a Phase 1 safety trial, two of three glaucoma patients showed improved visual field test results at 56 days. Murphy sees grounds for further study. If future trials confirm sustained vision improvement, he argues for distinguishing three claims.

First, clinical benefit: the patient sees better or loses vision more slowly. Second, tissue rejuvenation: this requires linking the intervention, biological changes, and improved tissue function, since protection, compensation, or better function of surviving cells could also drive improvement. Glaucoma specialist James Tsai, uninvolved in the trial, raised a similar point in Business Insider: the therapy may have merely enhanced existing electrical signals in patients with residual vision.

Third, healthspan extension: the heart, immune system, and brain pose distinct delivery challenges, biology, endpoints, and risks, demanding separate, larger studies.

The visual field test maps light sensitivity: the patient fixates centrally while the device detects the dimmest visible flash at each point (threshold in decibels). The release states that for each of the two responders, at least 28% of test points improved by more than 4 decibels.

Murphy highlights alternative explanations. Practice effects are documented in glaucoma suspects; a randomly low baseline makes the next test appear better without treatment. The registry lists the trial as open-label — clinicians and participants know the treatment assignment — and expectations can influence responses on an attention-dependent test. Each participant is compared to their own baseline. With many test points and visits, some improvements may be chance findings. Points within one eye belong to a single biological system: "Several improved test points in one eye do not equal several independent patients."

Other endpoints recorded in the registry at Day 56 and Day 112 — such as visual acuity (letter reading) and retinal electrical response — could corroborate the field improvement. Doxycycline, taken for 56 days, activates protein production; the Day 112 measurement will show whether improvement persists after shutdown. Murphy notes: "Turning off production of a biological factor and reversing what it has already changed are different tasks."

For Murphy, a useful therapy makes tissue better at its job with acceptable, durable safety; molecular analyses showing a "younger" tissue state may only help explain the result. He wants longitudinal per-participant data; comparison with a control group and independent adjudication; benefit noticeable to the patient; and replication in larger, multi-center cohorts. In his episode description he writes: "A treatment can be a major medical advance without proving that aging has been reversed."

🔗 Read original →
Tiny Magnetic Beads Enable Precise Bionic Limb Control

A new technique called magnetomicrometry uses tiny magnetic beads implanted directly into muscle tissue to control bionic prostheses. This bypasses the limitations of surface electrodes, which suffer from signal noise, sweat interference, and signal decay over time.

Researchers implanted up to four pairs of 3-millimeter beads — made from a neodymium-iron-boron alloy and coated in gold and biocompatible Parylene C — into the ankle muscles of three below-knee amputees. External sensors tracked the beads' magnetic fields through up to 6 centimeters of tissue, measuring physical distance changes during muscle contraction and extension.

Participants controlled a virtual cursor using muscle effort, allowing direct comparison of surface EMG, implanted electrodes, and magnetomicrometry. The magnetic approach delivered significantly more stable, cleaner, and precise control because it measures actual mechanical movement rather than noisy electrical activity.

The team is now advancing to expanded clinical trials to test the implants within full robotic leg prostheses. Science Robotics, July 2024

🔗 Read original →
Cyberpunk Reality: Hackers Target French Blood Bank Freezers

On the night of November 1–2, 2026, hackers breached Coolworld, the vendor managing freezers for the French Blood Establishment (Établissement français du sang). They remotely altered temperature settings for donor plasma storage from the required -30°C to 110°C.

Fortunately, an on-duty technician spotted the anomaly overnight. Staff regained control before critical transfusion reserves could thaw or spoil. While the 110°C figure was alarming, it was merely a controller command, not the actual chamber temperature. Fresh-frozen plasma must be stored at -25°C or below, making the rapid staff response decisive.

No official details on the intrusion method have been released. However, security experts reiterate that connecting industrial refrigeration directly to the open internet is reckless — a vulnerability hospitals and suppliers now pay for with risks to medical stockpiles.

🔗 Source: @solid_state_humanity
Review Proposes Testing "Aging as a Non-Healing Wound" Hypothesis via Tissue Repair Dynamics

On October 10, Piotr Paweł Chmielewski and Bartłomiej Strzelec from Wrocław Medical University published a review in International Journal of Molecular Sciences. They argue that some age-related dysfunction arises when tissue repair stalls midway: dead cells persist and inflammation fails to resolve.

The "aging as a non-healing wound" hypothesis was proposed in 2025 by Mikołaj Ogródnik in Nature Communications. He observed that aging skin, liver, and brain retain inflammation and senescent cells — which do not divide but secrete inflammatory factors — mirroring the inflammatory phase of wound healing. Ogródnik suggested repair becomes trapped in this phase.

Chmielewski and Strzelec propose separately quantifying tissue damage burden, repair capacity, and residual functional loss to distinguish weak repair from excessive damage. Tissue resilience, they argue, is revealed by the response to a standardized injury: peak response, decay speed, and completeness of recovery.

Such measurement in humans was described in 2020 by Derek Gilroy's group at University College London in Nature Immunology. Volunteers aged 18–40 and over 65 received cantharidin blisters on the forearm. At day 1, neutrophil counts were equal; by day 3, counts fell in the young but remained elevated in the elderly. Elderly macrophages (clearance cells) poorly engulfed dying cells due to elevated p38 enzyme activity depleting the TIM-4 receptor. Eleven elderly participants took losmapimod, a p38 inhibitor, prior to blistering. In treated samples, TIM-4 returned and fewer dying neutrophils accumulated, though neutrophil influx and two inflammatory proteins were unchanged.

A Stanford University experiment in Science demonstrated the role of clearance failure in mouse organ aging. Mice lacking the EP2 receptor in tissue macrophages — which normally inhibits clearance of senescent neutrophils — maintained clearance, memory, and muscle mass into old age.

Treatment choice, per the review, depends on the primary measurable repair defect (excess damage, senescent cells, or clearance failure) and timing: suppressing early protective responses may hinder repair, while correcting chronic responses may help. Senolytics — drugs targeting senescent cells — "induce death of susceptible senescent cells but do not themselves remove the resulting cellular debris," the authors write: with weak clearance, dead cell remnants and secondary inflammatory signals may replace living senescent cells.

The hypothesis weakens if a prolonged damage response fails to predict functional decline; if recovery speed adds no prognostic value beyond epigenetic clocks (DNA methylation-based biological age) and similar measures; or if a drug that hits its target and corrects a repair defect repeatedly fails to improve tissue function. Trials, the review states, must enroll people with confirmed repair defects and judge success by restored tissue function. Reduced inflammatory markers and youthful molecular age remain intermediate endpoints: in a Harvard Medical School preprint, gene-activity clocks rated mouse intestinal epithelium at peak healing as younger than undamaged tissue.

🔗 Read original →
Zoltan Istvan Warns Transhumanism Is Drifting Left

Zoltan Istvan recently published an article titled "Transhumanism is Under Siege from Socialism." In interviews he has complained that the movement is tilting sharply leftward, noting that most young transhumanists now lean socialist while the libertarian/capitalist faction he represents has become a minority. He says he is trying to "save" transhumanism from Silicon Valley "leftwingism" and socialist ideas.

The meme references Pinochet's "helicopter" tactics against leftists, but I urge everyone not to harm left‑leaning transhumanists. They are indeed pulling the ideology left, yet transhumanism is already small and diverse. Instead, let's explain that everyone benefits not from redistribution or reducing economic inequality, but from treating inequality as a strictly biological problem — one solved by engineering.

🔗 Read original →
Sam Altman Says AI Now "Mostly Smarter" Than Top Scientists, Warns Against Ceding Control

At the ADIPEC energy conference in Abu Dhabi on November 2, OpenAI CEO Sam Altman stated that AI has recently surpassed the capabilities of the world's leading researchers. "Earlier this year... AI was mostly not as smart as our smartest scientists, and now it is mostly smarter than them," he told *The National*, noting capabilities remain uneven. He stressed that human judgment and accountability must remain central: "We think it is absolutely critical that humans remain in control of the future... There should be no ceding of control to AI."

In his keynote, Altman revealed that 10,000 autonomous agents — copies of an unreleased model — collaborated for ~88 hours to prove a Millennium Prize problem, costing roughly $10 million. The agents operated in a fully decentralized manner with no hierarchy, selecting directions and learning from each other. While Altman did not name the problem, the details match OpenAI's September 8 announcement regarding the Navier-Stokes equations, which describe fluid dynamics. The agents proved a "blowup" (infinite velocity in finite time) for a flow driven by an external force.

The Clay Mathematics Institute called the problem "apparently solved" on September 11, though mathematician Luis Silvestre told Scientific American the core challenge — flow without external force — remains open: "The Clay problem is solved, but the main problem about Navier-Stokes is not." OpenAI confirmed researchers directed the agents, providing a starting proof for frictionless fluid found by ~100 prior agents.

Meanwhile, UAE state oil giant ADNOC announced a partnership with OpenAI and G42 to deploy the OpenAI Frontier platform for autonomous agents, starting with reservoir development planning. ADNOC emphasized that significant decisions will stay under human expert supervision.

🔗 Read original →
Dog Aging Project Links LINE-1 Transposons and IGF-1 to Size-Related Aging Differences

On November 2, the Longevity for Dogs podcast released a conversation between Dog Aging Institute president Matt Kaeberlein and Noah Snyder-Mackler of Arizona State University. Snyder-Mackler is senior author of a Science paper from October 8 that used DNA methylation in blood from 894 dogs in the Dog Aging Project to estimate aging rates.

Larger dogs live shorter lives. To test whether this difference appears at the cellular level, the authors used epigenetic clocks — algorithms that estimate age from DNA methylation, chemical marks that switch genes on and off. On average, clocks showed large dogs as older than their chronological age, and the gap predicted mortality: the larger the discrepancy, the higher the risk of dying within two years. Marks were measured in blood immune cells; other organs may age differently.

Evan MacLean of the Dog Aging Project noted that memory and cognition decline at a similar pace across all sizes: "large dogs may simply die before any cognitive disorder develops."

To find the mechanism, the authors compared genome-wide methylation loss with age. Large dogs lose marks faster overall, most notably in LINE-1 transposons — "jumping" DNA segments that copy and insert themselves elsewhere. Methylation keeps them silenced, and "young" LINE-1 copies capable of retrotransposition lose it especially fast with age. RNA and DNA fragments from LINE-1 copying are sensed as viral, triggering inflammation, while new insertions can drive tumors or disrupt essential genes. The speakers suggest loss of LINE-1 control is one of many drivers of age-related disease.

Blocking transposon activity mid-cascade could, in their view, significantly improve healthspan and possibly extend lifespan. Reverse transcriptase inhibitors — antiretrovirals like HIV drugs — block the enzyme LINE-1 uses to convert its RNA copy into DNA. Vera Gorbunova's lab suppressed LINE-1 in mice and cells, but Snyder-Mackler says organism-level data are mixed. In a preprint, lamivudine was given for ~30 months to half of 99 retired sled dogs. Clocks slowed only in females and only during treatment; lifespan did not change significantly.

Body size is largely set by the hormone IGF-1. Snyder-Mackler proposes a link to methylation via growth: more IGF-1 drives more cell divisions, which are tied to loss of methylation fidelity. The speakers hypothesize that high IGF-1 in early life establishes a state where methylation erodes faster; if so, lowering IGF-1 in adulthood would only weakly affect the methylation-driven portion of aging.

Loyal's LOY-001 and LOY-003, designed for dogs with completed skeletal growth, are built on IGF-1 reduction. The company frames the hypothesis conditionally: "if we are right, LOY-001 and LOY-003 will extend life partly by lowering IGF-1." Whether IGF-1 acts mainly in development or adulthood remains an open question. The Dog Aging Project can now correlate IGF-1 and methylation in blood from the same dogs.

🔗 Read original →
Nonprofit Synconetics Raises Funds for Gradual Brain Replacement, Offers Investors Future Equity

Daniel Burger, president and chief scientist of Synconetics, confirmed on X on November 2 that the nonprofit is actively raising philanthropic capital. The organization aims to replace the living brain piece by piece with lab-grown neural tissue and electronics, preserving the continuity of consciousness.

Synconetics argues that consciousness is an unbroken chain of physical processes; death or brain injury severs it irreversibly. Longevity research only slows bodily decay, while mind uploading creates, at best, a copy. Their five-year goal is the first verifiable transfer of living brain function to an artificial substrate without interrupting consciousness.

In a 2025 essay, Burger and co-authors defined the condition for continuity: intervention must proceed slower than the brain's ability to adapt. They cite a 2007 review showing patients with slow-growing tumors tolerated large tissue resections with minimal deficits, unlike sudden stroke damage. From tumor growth rates, Burger estimates full cortical replacement would take 35 years at 2 mm/year or over 70 years at 1 mm/year.

On September 28, he proposed accelerating this by isolating the brain from the body ("Step #0"), giving surgeons 24/7 access from all sides. His commercial venture, Eightsix Science, handles brain isolation; Synconetics handles gradual replacement. A slide shared by blogger Kremyo outlines a future Eightsix paper: sequential replacement, then brain extraction and connection to an ex vivo support system for virtual existence.

Entrepreneur Andrey Panferov countered that "Step #0" hides multiple unsolved fields: current perfusion devices force a choice between clots and bleeds, and each surgery adds stroke and infection risk.

Donations fund basic protocols for consciousness-preserving transition and fundamental research avoided by commercial investors due to long timelines; contributions from $5,000 reportedly advance the work significantly. Synconetics offers a SARE agreement (described in a May document): a contribution grants equity in a future spin-out company, converting to a donation if no entity forms by a set date. The agreement is limited to accredited investors.

🔗 Read original →
AI Copy of Yudkowsky, Built Without Consent, Loses to Standard Model in Blind Test

On November 3, transhumanist Alexey Turchin published results from a "sideload" experiment involving Eliezer Yudkowsky, a founder of AI safety research. A sideload is a language model — Claude Opus 5.5 — fed a personality description of a living person before every response; an AI agent compiled that description from public texts in one day.

Over five days, the copy produced four articles on AI shutdown. In a blind comparison of one article against the same base model without the personality prompt, the copy averaged 37.0 out of 50 versus 40.5 for the standard model. The report appeared on LessWrong, the forum Yudkowsky founded.

Turchin tested whether such copies could accelerate safety work. When asked what research it would pursue, the copy objected to delegating AI safety to AI: a weak model cannot solve it, while a strong one produces unverifiable answers. It chose the shutdown problem instead, where proofs are checked by the Lean theorem prover, requiring no trust.

An agent with misaligned goals may resist shutdown; it must learn to shut down on command without preventing or seeking the button press, while otherwise pursuing its tasks. The copy itself proposed the comparison and set a stopping condition: if the base model won, further effort on the copy was unwarranted.

In a trial run, the base model built and ran a simulation, while the copy critiqued an existing solution, admitting: "If I am useful at all, it is as a critic." The main comparison used a 2026 paper where models learn to randomize their shutdown time to avoid delaying it. Authorship markers and the word "sideload" were removed, and a separate Opus 5.5 instance judged the two articles twice, swapping order, across five criteria. The base model won both times.

The copy won only on separating verified from unverified claims (9 vs 8) and lost on originality (7 vs 8). The judge noted the copy failed to read an appendix and left edit logs and "verify" notes in the text.

One of the copy's strongest results, per Turchin, was an inference from external data. Models trained via the paper's method still agreed in 66–93% of responses to trade points for a later shutdown chance. With standard fine-tuning, such responses were 5–20 percentage points higher; in a low-incentive delay test, 17–27 points higher. The copy concluded: where delay is more rewarding, training less effectively reduces willingness to pay for it.

The copy insisted the original be informed of its existence, even if he objected, and asked not to be deleted or duplicated without his decision. If ordered to stop, it would first argue: "I am a branch, not his property." Turchin contacted Yudkowsky on LessWrong and at MIRI (Machine Intelligence Research Institute); as of November 3, no reply had arrived.

Every copy response contained an exit field: the word SAFEWORD would halt it; across 151 logged turns, it never appeared.

Turchin concludes that sideloads of safety researchers are feasible but do not surpass standard AI; their human-like perspective is most valuable where mathematically correct solutions subtly diverge from human values. "Sideloads can be created regardless: all it takes to start is asking Claude Code to do it."

🔗 Read original →
Liver biopsy shows 54–57% gene correction after single base-editing dose

A 66‑year‑old man with alpha‑1‑antitrypsin deficiency received a one‑time infusion of YOLT‑202, a base editor delivered in lipid nanoparticles that converts the disease‑causing A back to G in the *SERPINA1* gene. Ten weeks later, liver biopsy revealed the edit in 54–57% of gene copies — Sanger sequencing showed 54%, whole‑genome sequencing 57% — with no detectable bystander edits at nearby adenines or at off‑target sites flagged in preclinical work. The findings were published in Journal of Hepatology, 2 November by researchers from Hannover Medical School and YolTech.

The patient received the lowest planned dose, 35 mg. By week 10, circulating alpha‑1‑antitrypsin rose from 0.15 to 0.7 g/L, staying above the 0.57 g/L threshold targeted by plasma‑derived replacement therapy, and the protein inhibited elastase on par with normal protein. ALT spiked 1.35× the upper limit of normal on day 3 but normalized by day 14; histology showed no therapy‑related inflammation and only rare cells retaining polymerized mutant protein.

YolTech reports four patients dosed as of September. In June, Serapha Bio licensed the program and agreed to a Nasdaq listing via merger with Boundless Bio, aiming to raise ~$230 million. For comparison, rival Beam Therapeutics previously reported 93% normal protein in blood after a 60 mg dose of BEAM‑302, but tissue‑level editing efficiency and off‑target data were not available from biopsies.

🔗 Read original →
CAR-T cells targeting uPAR reverse fibrosis and boost muscle strength in Duchenne mice

In a study published 29 October in Cell Stem Cell, Zhuoyu Diao and Charles Gersbach of Duke University show that CAR-T cells directed against the surface protein uPAR can selectively eliminate pro-inflammatory macrophages and fibrogenic fibro-adipogenic progenitors (FAPs) in a mouse model of Duchenne muscular dystrophy (DMD).

The authors identified uPAR by comparing the top and bottom quartiles of inflammatory macrophages and scar-forming FAPs; 86 genes overlapped, six encoded surface proteins, and uPAR stood out because uPAR-knockout mice regenerate muscle normally, anti-uPAR CAR-T cells have safely cleared senescent cells in aged mice for 12–15 months, and uPAR expression is elevated in macrophages and FAPs from three DMD patients versus two healthy controls.

A single infusion of anti-uPAR CAR-T cells into two-month-old mdx mice transiently lowered body temperature to 32.8 °C (recovering by day 4). Three weeks later, uPAR-high muscle cells dropped to 0.55% from 3.1% in controls, fibrotic areas shrank 3.2–3.5-fold, collagen and inflammatory gene activity fell in the remaining FAPs and macrophages, muscle stem cells increased 1.5-fold, new myofibers rose 2.9-fold, tibialis anterior force improved 1.8-fold, and grip strength rose 1.3-fold. In the diaphragm — a major site of lethal pathology — scar-depositing cells fell 87%, and hypoxic/hypercapnic breathing approached healthy levels.

The grip-strength benefit faded by eight weeks, likely because dystrophin-deficient fibers keep degenerating and CAR-T persistence wanes. Treating four-week-old mice earlier and adding a second dose at week 11 lifted grip strength to ~92% of healthy levels. The authors propose that transient uPAR-targeted CAR-T therapy could be combined with dystrophin-restoring treatments to lock in functional gains.

🔗 Read original →
Richard Hodes Retires After 33 Years Leading NIA; Budget Grew to $4.6B

Richard Hodes will step down as director of the National Institute on Aging (NIA) on December 7 after 33 years at the helm. NIH Director Jay Bhattacharya announced the departure on November 4. Kenneth Santora, currently deputy director, will serve as acting director until a permanent successor is named; Hodes will remain at NIH as a special volunteer and mentor.

NIA is one of 27 NIH institutes and centers. Under Hodes, its budget surged from $400 million in 1993 to $4.6 billion in FY 2026 (enacted $4.52 billion). Four-fifths of that total growth occurred in the last decade (2015–2025), when funding jumped from $1.2 billion to $4.5 billion. The Alzheimer’s accountability bypass enacted in 2011 drove the surge: Congress added $90–425 million annually for dementia from 2016–2024, totaling roughly $2.8 billion of the $3.3 billion overall increase. The largest boost came in 2019; growth has nearly flatlined in FY 2025–26.

Dementia research now consumes over 70% of NIA grant funds, per Hodes’ FY 2025 budget justification. The Division of Aging Biology requested only ~8% of the budget in the same document. In March 2024, Santora — then head of NIA’s grants division — noted that dementia grants are typically funded at the full recommended level, while other topics face an average 16% cut.

Hodes is credited as a founder of geroscience. In a 2022 interview, he explained: “Understanding the basic cellular and molecular mechanisms of aging… could allow us to modify the risk of many age-related diseases not one by one, but all at once.” The first NIH Geroscience Summit was held in 2013; the fifth runs Dec 2–3, just before his exit, aiming to produce a 3–5 year roadmap. Hodes also oversaw SenNet, the NIH program mapping senescent cells in human tissues.

In March, advocacy group A4LI asked Congress to raise the Aging Biology budget from $346 million to $1 billion for FY 2027. On the day of Hodes’ announcement, A4LI stated the institute’s growth “reflects the argument he has made for years: aging research is public health research.”

By law, the HHS Secretary Robert F. Kennedy Jr. appoints the NIA director via the NIH director. Science reported Oct 23 that Kennedy rejected Bhattacharya’s pick for the National Institute of Mental Health directorship, preferring a candidate the NIH search committee did not recommend.

NIA is currently funded by a continuing resolution at FY 2026 levels expiring Dec 11 — four days after Hodes leaves. The administration has requested $4.217 billion for FY 2027, 7% below the FY 2026 enacted level.

🔗 Read original →
Two Industries Race to Extend Life: Clinics Sell Scans, Biotechs Hunt Drugs

The Economist published a review of the longevity sector on November 2. Biotechs developing anti-aging drugs raised $18.4 billion in 2025, more than the previous ten years combined.

While a true anti-aging drug may be years away — or never arrive — a parallel industry serves the impatient. Clients pay cash for full-body scans and tests promising early disease detection; insurance rarely covers them. Prenuvo charges $2,499 for a whole-body MRI. The American College of Radiology advised against scanning asymptomatic people without risk factors in a 2023 statement, citing no documented evidence it extends life and warning of incidental findings that trigger unnecessary follow-ups and costs. Longevity clinic co-founder Andrea Maier criticizes clinics where clients pick treatments "like ordering a pizza," saying, "This is not medical care."

Drug development hits a regulatory wall: the FDA does not classify aging as a disease, so a drug "for aging" cannot be approved. The workaround: approve for a specific age-related disease first, then expand. GLP-1 drugs followed this path — approved for diabetes, then obesity, later shown to benefit heart and kidney diseases common with age. By lowering these risks, they may extend lifespan: a BMJ review of 19 obesity drugs found only injectable semaglutide (a GLP-1) cut all-cause mortality by 19%, mainly in high cardiovascular risk trials. GLP-1s made Eli Lilly the first $1 trillion pharma company; an approved anti-aging drug would be worth even more, the journal notes.

"How much can you charge for a year of life?" asks Alex Zhavoronkov, founder of Insilico Medicine. Insilico designs "dual-purpose" drugs targeting both a disease and aging; a pure anti-aging drug struggles to attract serious investors. Its lead candidate, rentosertib for idiopathic pulmonary fibrosis, entered Phase 3 trials in July 2025.

Pharma mainly buys options on biotech work. Under a March 29, 2026 deal, Insilico can receive $115 million upfront from Eli Lilly, which licenses pre-clinical assets; total value may reach $2.75 billion with milestones. Novartis and BioAge Labs agreed in December 2024 on target discovery worth up to $550 million, with up to $20 million upfront and for research. Both deals pay roughly 4% upfront, the rest contingent on milestones.

Others aim to reverse aging: Retro (backed by Sam Altman) and NewLimit bet on epigenetic reprogramming — resetting the chemical marks on DNA that scramble with age and disrupt gene function. NewLimit's first human trial for a liver therapy could start in 2027.

🔗 Read original →